MAP - Market Access Podcast

How Can Europe Move from Innovation Paradox to Powerhouse,  Cuno Moser?

01 May 2026

Contributed by Lukas

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer engages with Swiss healthcare strategist Cuno Moser to explore Europe's ...

Continuous Insight, Not One-Off Studies: Are Primary Research Platforms Defining a New Era, Shrutya Bhalla?

15 Apr 2026

Contributed by Lukas

In the latest episode of the MAP – Market Access Podcast, Dr. Stefan Walzer speaks with pricing and access expert Shrutya Bhalla about how primary r...

How Can Political Leadership Turn Health into an Economic Priority, Hatice Küçük Benton?

01 Apr 2026

Contributed by Lukas

In this episode of the MAP – Market Access Podcast, Dr. Stefan Walzer speaks with Hatice Küçük Beton, Executive Director of the G20 Health and De...

Is Europe Still More Attractive Than the US, China, India or MENA for Medtech Investment, Bernard Bichsel?

15 Mar 2026

Contributed by Lukas

In the latest Market Access Podcast episode, host Stefan Walzer sits down with Bernard “Bernie” Bichsel – one of Europe’s most experienced voi...

From Necessary Tasks to New Insights: How Can AI Act as a Sparring Partner in Market Access, Helmut Butscher?

01 Mar 2026

Contributed by Lukas

In this episode, Stefan Walzer talks with experienced Market Access manager Helmut Butscher about concrete AI applications across the full Market Acce...

Can Innovative Contracting Turn High‑Cost Therapies into Sustainable Deals, Omar Ali?

15 Feb 2026

Contributed by Lukas

In this thought‑provoking Market Access Podcast episode, host Stefan Walzer sits down with Omar Ali – Head of Payers at Vipora, former NICE adviso...

What Makes Australia’s HTA Approach to Equity and Health Productivity Unique, Zanfina Ademi?

01 Feb 2026

Contributed by Lukas

In this Market Access Podcast episode, Dr. Stefan Walzer sits down with Prof. Zanfania Ademi, a health economist at Monash University, to explore how ...

No Decisions for Us, Without Us: Why Patient Advocacy Matters in Market Access, Erica Bersin?

15 Jan 2026

Contributed by Lukas

In this episode of the Market Access Podcast, Erica Bersin—founder of ERO Health Communications—joins Dr. Stefan Walzer to discuss the changing ro...

Can VR and AR Finally Break Through the Barriers in Medical Innovation, Günter Illert?

15 Dec 2025

Contributed by Lukas

In this episode of the Market Access Podcast, Dr. Stefan Walzer sits down with strategy consultant and XR advocate Günter Illert to explore how virtu...

Why Should Pharma and MedTech Innovators Look at New Zealand, Julius Ohrnberger?

01 Dec 2025

Contributed by Lukas

Tune in to this new episode of MAP to explore New Zealand’s unique healthcare and reimbursement landscape with Dr. Stefan Walzer and health economis...

Are We Ready for a Cultural Shift Toward AI in Pharma, Elizabeth Shanahan?

15 Nov 2025

Contributed by Lukas

In this brand new episode of MAP - the Market Access Podcast, Dr. Stefan Walzer sits down with Elizabeth Shanahan, AI Strategy Lead at Sanofi, for a r...

What Can Europe and the U.S. Learn from Each Other on Market Access, Anne Loos?

01 Nov 2025

Contributed by Lukas

Tune in to this new episode of MAP, the Market Access Podcast, where Dr. Stefan Walzer is joined by Anne Loos from Wickenstones, to explore the evolvi...

Will AI and Living Reviews Define the Next Era of Health Policy, Anna Forsythe?

15 Oct 2025

Contributed by Lukas

Join this episode of MAP – The Market Access Podcast as Dr. Stefan Walzer sits down with Anna Forsythe, founder of OncoScope-AI, to explore how Livi...

Are We Undervaluing the Economic Power of Health, Dr. Malina Müller?

01 Oct 2025

Contributed by Lukas

In the latest MAP Podcast, our host Dr. Stefan Walzer is joined by Dr. Malina Müller from the WifOR Institute to rethink how we value health. From re...

How Should Pharma Respond to the New Reality of Market Access in Germany, Prof. Dr. Thomas Hammerschmidt?

15 Sep 2025

Contributed by Lukas

In this episode of MAP - the Market Access Podcast, Dr. Stefan Walzer sits down with expert Prof. Dr. Thomas Hammerschmidt, to dive deep into Germany’...

Do Swiss Reimbursement Reforms Open Doors—or Raise New Barriers, Petra Erni?

01 Sep 2025

Contributed by Lukas

Tune in to this episode of MAP – The Market Access Podcast, to hear from Dr. Stefan Walzer as he speaks with Swiss reimbursement expert Petra Erni, ...

The Startup Guide to Navigating Healthcare Reimbursement, Featuring Ron de Graaff (Repost)

15 Aug 2025

Contributed by Lukas

This is a repost of a popular episode of MAP - Market Access Podcast, from December 1st 2023.We are thrilled to announce our latest podcast episode, f...

Europe vs. US: Who Leads the Future of Market Access, Dr. Doug Niven?

01 Aug 2025

Contributed by Lukas

In this thought-provoking episode of MAP, the Market Access Podcast, Dr. Stefan Walzer sits down with strategic Market Access consultant Dr. Doug Nive...

What Does It Really Take to Master AMNOG in Today’s Market Access Landscape, Anja Pownell?

15 Jul 2025

Contributed by Lukas

Tune in to this new episode of the Market Access Podcast, where our host Dr. Stefan Walzer is joined by AMNOG expert Anja Pownell to bust some of the ...

Is Cross-Functional Alignment the Secret to Successful Market Access, Kasem Akhras?

01 Jul 2025

Contributed by Lukas

In this episode of the Market Access Podcast, Dr. Stefan Walzer sits down with Kasem Akhras, veteran access strategist and author of Frontiers in Mark...

How Do You Unlock the Power of Statistics in Market Access, Necdet Gunsoy?

15 Jun 2025

Contributed by Lukas

Tune in to the latest episode of the Market Access Podcast, where Dr. Stefan Walzer welcomes statistician and Evimed founder Necdet Gunsoy to explore ...

How will AI shape the future of Market Access and Systematic Reviews, Jeffrey Johnson and Kevin Kallmes? (Repost)

01 Jun 2025

Contributed by Lukas

This is a repost of a popular episode of MAP - Market Access Podcast, from July 15th 2024.Unlock the Future of Market Access with AI and Systematic Li...

How Can Market Access Professionals Plan for Long-Term Success, Adrian Kielhorn?

15 May 2025

Contributed by Lukas

What does it take to succeed in Market Access? In this brand new episode of MAP, the Market Access podcast, Dr. Stefan Walzer sits down with industry ...

What Are the Biggest Challenges & Opportunities of JCA, Dr. Nick Leach?

01 May 2025

Contributed by Lukas

In this brand new episode of MAP, the Market Access Podcast, our host Dr. Stefan Walzer is joined by Dr. Nick Leach, Market Access expert and managing...

Are We Overlooking the Real Benefits of Medical Innovation, Dr. Ahmed Seddik?

15 Apr 2025

Contributed by Lukas

Join the latest episode of the Market Access Podcast, where our host Dr. Stefan Walzer and expert Dr. Ahmed Seddik dissect the complexities of th...

What Are the Biggest Challenges in Implementing AI in Pharma, Jan Kroschinski?

01 Apr 2025

Contributed by Lukas

How can AI revolutionize Market Access, and what does it take to drive successful change in pharma? Tune into the latest episode of MAP, the Market Ac...

How Can Startups Leverage Market Access to Attract Investors, Johan Olsson?

15 Mar 2025

Contributed by Lukas

In the latest episode of MAP, the Market Access Podcast, our host Dr. Stefan Walzer sits down with Johan Olsson, a seasoned life sciences investor, to...

How Are Data Privacy Laws Delaying Patient Access to New Treatments, Douglas Drake and Adam Skali?

01 Mar 2025

Contributed by Lukas

In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect...

How Can Innovation Planning Transform Market Access Success, Dr. Kasia Hein-Peters?

15 Feb 2025

Contributed by Lukas

Tune in to the latest episode of MAP, the Market Access Podcast, where Dr. Stefan Walzer sits down with Amazon bestselling author Dr. Kasia Hein-Peter...

How does early Market Access bridge the gap between innovation and commercial success, Catherine Bacon?

01 Feb 2025

Contributed by Lukas

Discover the newest episode of MAP, the Market Access Podcast, your go-to podcast for all things Market Access. In todays episode our host Dr. Stefan ...

A Flourishing Career in Pharmaceutical Market Access: Which Skills Are Essential, Dipti Tankala? (Repost)

15 Jan 2025

Contributed by Lukas

This is a repost of a popular episode of MAP - Market Access Podcast, from March 15th 2024.Explore the inspiring journey of Dipti Tankala in this podc...

What happens, when negotiations fail, Prof. Dr. Jürgen Wasem? (Repost)

15 Dec 2024

Contributed by Lukas

This is a repost of a popular episode of MAP - Market Access Podcast, from December 15th 2021.Who could be better to tell us the real insights, h...

How can people get equal access to pharmaceuticals, Dr. Nina Lathia? (Repost)

01 Dec 2024

Contributed by Lukas

This is a repost of a popular episode of MAP - Market Access Podcast, from April 15th 2023.All patients within all populations should have access to h...

How might digitization change health care in Germany by 2035, Julian Molitor? (Repost)

15 Nov 2024

Contributed by Lukas

This is a repost of a popular episode of MAP - Market Access Podcast, from October 1st 2022.Digital health could improve the efficiency, care and way ...

How to optimize commercialisation of innovative life science products, Dr. Kasia Hein-Peters? (Repost)

01 Nov 2024

Contributed by Lukas

This is a repost of a popular episode of MAP, Market Access Podcast, from 15th of July 2023.Even though there are great accelerators and a lot of inno...

What does environmental sustainability mean for Market Access, Gerdi Strydom?

15 Oct 2024

Contributed by Lukas

Join us on the latest episode of MAP - the Market Access Podcast - where our host Dr. Stefan Walzer, together with special guest Gerdi Strydom, Managi...

What are the main obstacles in oncology market access, Ed Schoonveld? (Repost)

01 Oct 2024

Contributed by Lukas

This is a repost of a popular MAP, Market Access Podcast, from 1st of January 2023. Companies launching oncology drugs sometimes struggle wi...

Is there a place for Real World Evidence in HTA, Dr. Karen Facey? (Repost)

15 Sep 2024

Contributed by Lukas

This is a repost of a popular MAP, Market Access Podcast, from January 2023. A strong evidence package is important as a solid base for health te...

How should market access and medical affairs work together, Dr. Mike Rosenblatt? (Repost)

01 Sep 2024

Contributed by Lukas

In this repost of MAP, the Market Access Podcast, from 15th of September 2023, you’ll hear from Dr Stefan Walzer and Dr Mike Rosenblatt as they’re...

Summer Special - Webinar: How AI can revolutionize dossier writing, with special guest Aleksey Zavgorodniy

15 Aug 2024

Contributed by Lukas

Tune in to the latest episode of MAP, the Market Access Podcast, hosted by Dr Stefan Walzer. In this summer special you will hear some profound insigh...

What are the latest trends in Turkish Healthcare Market Access, Oznur Seyhun?

01 Aug 2024

Contributed by Lukas

Join us on the latest episode of MAP - the Market Access Podcast - hosted by Dr. Stefan Walzer, as we delve into the dynamic world of market access in...

How will AI shape the future of Market Access and Systematic Reviews, Jeffrey Johnson and Kevin Kallmes?

15 Jul 2024

Contributed by Lukas

Unlock the Future of Market Access with AI and Systematic Literature Reviews! Join Dr. Stefan Walzer in the latest episode of the Market Access Podcas...

How can Virtual Reality become a game-changer in Healthcare Training, Rodrigo Silva?

01 Jul 2024

Contributed by Lukas

Tune in to the new episode of the Market Access Podcast (MAP), where Dr. Stefan Walzer, a pioneer in Market Access 4.0, explores groundbreaking soluti...

How Can AI Unlock the Potential of Market Access, Sandip Shah?

15 Jun 2024

Contributed by Lukas

In the latest episode of MAP - the Market Access Podcast, Dr. Stefan Walzer discusses the transformative power of AI with industry veteran Sandip Shah...

What Does the Future Hold for AI in Healthcare, Aleksey Zavgorodniy?

01 Jun 2024

Contributed by Lukas

What will the future of AI in healthcare look like? Join us in the latest episode of MAP, the Market Access Podcast, featuring Alexey Zavgorodniy...

How to Decode Market Access in Canada: Are There Essential Tips for Success, Tara Cowling and Jody Filkowski?

15 May 2024

Contributed by Lukas

In the newest episode of MAP - the Market Access podcast, experts Tara Cowling and Jody Filkowski unpacks the complexities and nuances of Canada's mar...

How has virtual become reality in market access, Glib Kutepov?

01 May 2024

Contributed by Lukas

What role will AI & VR transformations play in the future? Tune in to this fascinating episode of the Market Access Podcast to hear as our special...

What Makes Italy's Healthcare System So Complex, Giacomo Matteo Bruno?

16 Apr 2024

Contributed by Lukas

Tune into a brand new episode of the Market Access Podcast to listen to an intriguing conversation about the Italian healthcare system with Giacomo Ma...

Is Healthcare Just a Business in the US, Aymeric Chaupin?

01 Apr 2024

Contributed by Lukas

In this captivating episode of MAP, the Market Access Podcast, we welcome Aymeric Chaupin, a seasoned expert in pricing and market access. Aymeric's u...

A Flourishing Career in Pharmaceutical Market Access: Which Skills Are Essential, Dipti Tankala?

15 Mar 2024

Contributed by Lukas

Explore the inspiring journey of Dipti Tankala in this podcast episode as she delves into market access within the pharmaceutical industry. From facin...

Mastering US Market Access: What are proven Strategies for Success, Paul-Lukas Hoffschmidt?

01 Mar 2024

Contributed by Lukas

In this essential episode of the Market Access Podcast, we're diving deep into the critical aspects of commercializing healthcare innovations in the U...

Beyond the CE Mark: How can we achieve Medtech Reimbursement in France, Dr. Benoit Salaun?

15 Feb 2024

Contributed by Lukas

Join us for a fascinating dive into the complexities of French market access with our latest episode of the Map Podcast. Dr. Stefan Walzer, health eco...

Remo Christen – Early paid access in Switzerland – Switzerland, wonderland? (Repost)

01 Feb 2024

Contributed by Lukas

In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement including the famous article 71,...

How can we overcome the complexity of market access for medical devices in Spain, Sergio Gil?

15 Jan 2024

Contributed by Lukas

Are you intrigued by the pulsing heart of Spain’s healthcare sector, or are you considering navigating the vibrant market of medical devices in Spai...

What is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian? (Repost)

15 Dec 2023

Contributed by Lukas

We are looking at Israel a lot recently, but did you know how innovative this rather small country is in terms of healthcare?Israel spends only 7.6% o...

The Startup Guide to Navigating Healthcare Reimbursement, Featuring Ron de Graaff

01 Dec 2023

Contributed by Lukas

We are thrilled to announce our latest podcast episode, featuring a riveting conversation between our CEO Dr. Stefan Walzer and the esteemed healthcar...

Navigating the Healthcare Startup Galaxy - key insights with Dr. Thomas Kerscher and Mark Anken.

15 Nov 2023

Contributed by Lukas

🎧 Excited to share our CEO, Dr. Stefan Walzer's newest Market Access podcast episode that's nothing short of a masterclass for healthcare startups ...

How to navigate complexities, Aurelie Moser: Market Access in Digital Health vs. Drugs?

01 Nov 2023

Contributed by Lukas

🎙️ Exciting Podcast Episode Is Here! 🎙️In this episode of our podcast series, I'm excited to share that Stefan Walzer, a seasoned reimbursem...

AMNOG 2.0 - significant changes for the industry since January 2023, correct - Dr. Flume?

15 Oct 2023

Contributed by Lukas

Join us in the latest episode where pharmacist and head of a regional physicians association, Matthias Flume, engages in a thought-provoking discussio...

Inside the Swiss decision-makers - how does the system for drugs really work, Dr. Heiner Sandmeier?

01 Oct 2023

Contributed by Lukas

Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi Switzerland is seen as a small but still attractive market...

How should market access and medical affairs work together, Dr. Mike Rosenblatt?

15 Sep 2023

Contributed by Lukas

Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTiWe are living in an age of massive medical innovation including ...

📠 How will Switzerland make the leap from FAX machines to Digital Healthcare, Dr. Peter Indra?

01 Sep 2023

Contributed by Lukas

🎧 Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi  🇨🇭Switzerland has one of the highest heal...

How does an optimized communication strategy look like, Dr. Arne Näveke?

15 Aug 2023

Contributed by Lukas

Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTiCompanies, including start-ups, are usually focused solely on th...

How does the German evaluation committee work, Prof. Jürgen Wasem?

01 Aug 2023

Contributed by Lukas

Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi New methods such as diagnostics need to be assessed and th...

How to optimize commercialisation of innovative life science products, Dr. Kasia Hein-Peters?

15 Jul 2023

Contributed by Lukas

Even though there are great accelerators and a lot of innovative product ideas, only very few products actually make it to the market and are commerci...

How do I get approved by the US FDA, Dr. Jamie Cross?

01 Jul 2023

Contributed by Lukas

In order to commercialize a health care product in the USA, the US FDA would need to approve it. But what is the standard process and how early would ...

How will the US Inflation Reduction Act change pricing of pharmaceuticals, Anita Burrell?

15 Jun 2023

Contributed by Lukas

The Inflation Reduction Act in the US will change fundamental how the US pharmaceutical industry works. The IRA will negotiate their own prices f...

How does market access work in Japan, Heather Wellam?

01 Jun 2023

Contributed by Lukas

The market access experts Dr. Stefan Walzer and Heather Wellam are discussing the market access process in Japan, one of the largest health care marke...

Would AI substitute or (only) support market access managers, Dr. Andree Bates? (Repost)

15 May 2023

Contributed by Lukas

Since the original publication of this podcast, AI has received enormous public attention, and we have also seen an amazing increase in performance. T...

Is there a place for Real World Evidence in HTA, Dr. Karen Facey?

01 May 2023

Contributed by Lukas

A strong evidence package is important as a solid base for health technology assessments and the following price negotiations with health care payers....

How can people get equal access to pharmaceuticals, Dr. Nina Lathia?

15 Apr 2023

Contributed by Lukas

All patients within all populations should have access to high quality medications that improve their health outcomes regardless of race, ethnicity, s...

How to be successful in Canadian health care market access & pricing!

01 Apr 2023

Contributed by Lukas

Canadian health care reimbursement might be seen as complex and difficult. Well, not totally wrong… The reimbursement veteran Dr. Stefan Walzer disc...

How can companies prepare for EU Joint HTA, Priyanka Kiritharan and Chloe Sheppard?

15 Mar 2023

Contributed by Lukas

EU Joint HTA will become reality for ATMPs and therapies in oncology by the end of 2024. Anyhow, methods and processes are not yet communicated a...

Is quality cancer care in Ukraine still possible, Yevgen Brovko?

01 Mar 2023

Contributed by Lukas

Cancer care is a challenge in all countries. Now imagine, how difficult it is to organize and manage cancer care in a war zone!  In this spe...

What are drivers for a positive approval by Health Canada, Fraidianie Sévignè?

15 Feb 2023

Contributed by Lukas

Regulatory processes might vary across the world, EMA and FDA are mostly known, but what are drivers by Health Canada? What to consider when expanding...

EU joint HTA – decided, but how will it be executed and how should companies prepare, Dr. Elvira Müller?

01 Feb 2023

Contributed by Lukas

In Europe, there are at least as many reimbursement assessment processes in place as European countries. Some of these are transparent and clearly def...

The US pricing reform has an impact on Europe as well, correct Dr. Renato Dellamano and Jack Mycka?!

15 Jan 2023

Contributed by Lukas

It seems to be a given, that prices in the US are higher than in the rest of the world. But what might happen, if the US refuses to pay these hig...

What are the main obstacles in oncology market access, Ed Schoonveld?

01 Jan 2023

Contributed by Lukas

Companies launching oncology drugs sometimes struggle with existing reimbursement pathways and negotiations with payers, mainly in Europe, but al...

Why should companies get early advice from payers, Esther Nzenza and Dr. Nick Leach?

15 Dec 2022

Contributed by Lukas

In Europe there are many different options to get engaged with payers across different jurisdictions. Given the complexity, the benefit of these might...

The AMNOG process - how does it work from a legal perspective, Alexander Meier?

01 Dec 2022

Contributed by Lukas

New, innovative drugs are assessed within the so-called AMNOG process in Germany. Given the legal nature of this process, lawyers also play an importa...

What are the hot topics in market access based on ISPOR Europe 2022, Dr. Stefan Walzer?

15 Nov 2022

Contributed by Lukas

In this special podcast episode Dr. Stefan Walzer jumps into the latest trends and researches around market access, reimbursement and pricing presente...

AMNOG Reform - will Germany remain the most attractive market for orphan drugs?

01 Nov 2022

Contributed by Lukas

Given the current reforms and adaptions in the German system, one can wonder if the German market might remain the most attractive to launch pharmaceu...

Why should Market Access Managers care about statistics, Alexander Schacht?

15 Oct 2022

Contributed by Lukas

Not everybody can be a statistician, but >The Effective Statistician< Alexander Schacht argues, that every Market Access Manager shoul...

How might digitization change health care in Germany by 2035, Julian Molitor?

01 Oct 2022

Contributed by Lukas

Digital health could improve the efficiency, care and way patients are treated in all health care systems in the next years. Germany has started by im...

Are selective contracts with German insurances a smarter reimbursement pathway, Tim Hering?

15 Sep 2022

Contributed by Lukas

Within the opportunity of contracting in the German health care market, prices, reimbursement and integrated care paths could be agreed on. However, f...

Would AI substitute or (only) support market access managers, Dr. Andree Bates?

01 Sep 2022

Contributed by Lukas

Dr. Stefan Walzer, market access expert, and his guest Dr. Andree Battes, expert in artificial intelligence (AI), are discussing the future ...

How successful is the DiGA fast track, Dr. Henrik Matthies ?

15 Aug 2022

Contributed by Lukas

Dr. Matthies used to be at the epicenter of the DIGA launch in 2020. He was the managing director of the Health innovation hub: digital health think t...

The UK market access has always been complex, now even more than before, Graham Foxon and Paul Craddy?

01 Aug 2022

Contributed by Lukas

The UK has always been on the forefront of market access with its unique pathways within England, but especially also considering Wales, Ire...

Switzerland is strong in many aspects, so also in its health care system, Dr. Peter Indra?

15 Jul 2022

Contributed by Lukas

The Swiss healthcare system is rather complex but at the same time quite effective. High expenditures into health care corresponds with high life...

AMNOG was the end of paradise for pharmaceutical companies, correct Prof. Hammerschmidt?

01 Jul 2022

Contributed by Lukas

What have been the main changes after 10 years of AMNOG for pharmaceutical companies? What have been the biggest successes within these years? For orp...

What is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian?

15 Jun 2022

Contributed by Lukas

Israel spends only 7.6% of the GDP on healthcare – significantly less than most other Western OECD countries. At the same time Israel has a higher l...

Dutch payers are pragmatic, especially when discussing medical devices, isn’t it, Ron de Graaff?

01 Jun 2022

Contributed by Lukas

The market access process in the Netherlands can be very special, especially for medical devices. Besides standard reimbursement processes with eviden...

The Belgium reimbursement pathway for digital health applications is similarly easy as in Germany, correct Katrien de Groote?

15 May 2022

Contributed by Lukas

Belgium has created a similar fast-track process as in Germany even though that some differences exist. Anyway, core question with new processes is al...

Is European market access really so difficult? Tell us the truth being successful in Europe, Esther Nzenza!

01 May 2022

Contributed by Lukas

Europe is one continent, with one Union (plus the UK)… Health policy is still the responsibility of each individual country and hence there are stil...

What can Europeans learn from Canada for the upcoming EU joint HTA, Gabriel Tremblay?

15 Apr 2022

Contributed by Lukas

EU joint HTA will become reality in the next few years as communicated recently by the European Commission. However, applicability and implementation ...

Digital Health Care is already fully utilized in the US, isn’t it?

01 Apr 2022

Contributed by Lukas

Dr. Stefan Walzer and Kate Claessens, the experienced consultant on healthcare in the US, are discussing the public acceptance as well ...

Does the Italian reimbursement pathway allow for innovative drugs being highly priced, Dr. Stefano Capri and Dr. Entela Xoxi?

15 Mar 2022

Contributed by Lukas

The Italian reimbursement system is unique in terms of its structure, especially also for innovative drugs. However, wha...

What are the specific elements about the Austrian market access pathway, Dr. Anna Bucsics?

01 Mar 2022

Contributed by Lukas

The Austrian market access pathway in the outpatient setting is unique in its pragmatic approach with their box system.The two experts on the Austrian...

The private health insurances as the entrance into German market access – is this true, Dr. Bastian Biermann?

15 Feb 2022

Contributed by Lukas

The German health care system consists of the statutory and private health insurances, whereas the latter covers around 10% of the population. Anyhow,...

How can a company derive the optimal price for their medical product, Dr. Renato Dellamano?

01 Feb 2022

Contributed by Lukas

What are drivers of pricing and ultimately negotiations? How can a global strategy best be implemented in individual countries? How do payers react to...